Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) will announce its first quarter 2021 financial results and corporate update on May 11, 2021, at 4:30 p.m. ET. The live call is accessible by phone or through a webcast on Otonomy's investor relations website. Otonomy focuses on developing innovative therapeutics for neurotology, utilizing unique drug delivery technology for sustained drug exposure, particularly in addressing hearing loss and tinnitus. The company holds a significant patent portfolio in this field. Further details can be found on their website.

Positive

• Pioneered new drug delivery technology for sustained exposure.
• Broad patent estate covering innovative therapeutics.
• Focus on unmet medical needs in hearing loss and tinnitus.

Negative

• None.

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on May 11, 2021.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 9497433. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Chloé-Anne Ramsey
Vice President
404.865.3601
cramsey@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

What is the date of Otonomy's Q1 2021 earnings report?

Otonomy's Q1 2021 earnings report is scheduled for May 11, 2021.

How can I access Otonomy's earnings call?

The earnings call can be accessed by phone or via a live webcast on Otonomy's investor relations website.

What does Otonomy focus on?

Otonomy focuses on developing innovative therapeutics for neurotology, particularly for hearing loss and tinnitus.